Health, Medical, Research, Science

A drug used for treating diabetes could cut risk of developing dementia…

METFORMIN

A drug used to treat diabetes could cut the risk of developing dementia by 20 per cent, a research study has found.

Around 15,000 people aged over 55 diagnosed with the type 2 form of the disease were given the drug metformin over a period of five years.

But when scientists looked back over medical records they found the drug also reduced the chance of those with diabetes developing dementia.

Metformin, one of the most common forms of treatments for diabetes, makes the body more sensitive to insulin, which diabetes sufferers cannot naturally produce.

About 800,000 people in the UK suffer from a form of dementia, with more than half being diagnosed with Alzheimer’s disease.

The Alzheimer’s Society in the UK said the study results were ‘positive news’ because diabetics are twice as likely to develop dementia as those who don’t have it. The Society has said that whilst this study is encouraging it is still not sure exactly how metformin works with regards to dementia. But it added:

… What is becoming increasingly apparent is the role of insulin in the brain and the way it can regulate the brains behaviour.

Clinical trials are now underway to test metformin as a therapy for both dementia and mild cognitive impairment.

The study by scientists at Kaiser Permanente was presented at the Alzheimer’s Association International conference in Boston earlier this week.

A statement issued by the Alzheimer’s Society said that due to the ‘huge cost’ of developing treatments ‘from scratch’ it was important to explore whether existing drugs could also treat dementia.

Standard
Britain, Foreign Affairs, Government, Military, National Security, Syria, United States

Arming the Syrian rebels is looking less likely…

SYRIAN REBELS

Downing Street has ditched plans to arm the Syrian rebels after the Prime Minister has been warned that there is little point sending weapons unless he is prepared for all-out war with the regime of Bashar al-Assad.

General Sir David Richards, Chief of the Defence Staff, along with other commanders believe that sending small arms or ground-to-air missiles will hardly be worth it, since it would it would make little difference to the outcome of the conflict. Military chiefs have also said that even options like a no-fly zone (NFZ) would require air attacks on Syrian defences that would last weeks or even months.

The assassination last week of Kamal Hamami, a top commander of the Syrian Free Army, by a hardline group linked to Al-Qaeda, has compounded anxieties over plans by Britain and other Western countries to give military help to rebels fighting the Assad regime. Those fears are aggravated by the possibility that weapons and expertise provided to the rebels could be turned against the UK and her allies by radical Islamists. There are also growing rivalries between the Syrian Free Army and Islamists, who have sometimes joined forces on the battlefield.

But senior ministers and Whitehall officials have revealed that the Coalition is drawing up plans to help train and advise ‘moderate’ elements of the opposition forces who continue to battle with Assad’s forces.

The British Prime Minister has been keen to act on Syria and demanded last month an end to the EU arms embargo on the country to give him options. The EU reluctantly relented, but sending weapons to the beleaguered rebels in Syria remains an option open to the prime minister if parliament was to approve, though that does seem a remote possibility at the present moment given the lack of support among Tory whips.

Following a meeting of the National Security Council, in which British military commanders were asked to present options on the conflict, the Government was told that although it might make them feel better (by sending weapons) it was hardly worth it in terms of altering the balance of forces on the ground. Whilst Syria is known to have good air defences, military chiefs have also said that engaging Syria militarily would mean weeks of bombing and air strikes. A decision to engage is one that couldn’t be undertaken half-heartedly.

But given the lack of organisation within the rebel movement, training and advising the rebels remain district possibilities for Britain. The UK is concentrating on areas where it feels it has the expertise to contribute. The supply of weapons into Syria is continuing to be made by Qatar and Saudi Arabia.

It is understood that military advisers could be stationed in Jordon to advise Syria rebel leaders on strategy and tactics. UK chiefs are wary of being accused of having British boots on the ground in Syria or by making any ground incursion into the country.

Ministers believe it could take 18 months of further conflict before Assad is forced to the negotiating table. The civil war has already claimed more than 100,000 lives with millions more displaced on the borders with neighbouring countries.

There is also frustration about the approach taken by US Secretary of State John Kerry in pushing regime figures to the negotiating table. There is little idea of the solution Mr Kerry is seeking. Knowing where you are trying to get to in order to get there should surely be central in any negotiations over Syria, but this underpinning remains distinctly absent even after almost three years of intense fighting.

Standard
Health, Medical, Research, Science

Indigestion drugs linked to risk of heart attacks and strokes…

PROTON PUMP INHIBITORS (PPIs)

Common indigestion drugs used by millions of Britons could increase the risk of heart attacks and strokes, according to research.

Scientists said the drugs, called proton pump inhibitors, or PPIs, can trigger a dangerous rise in chemicals in the body linked with heart disease.

Patients with existing heart problems, such as angina, are at most risk, but healthy adults with no history of such complaints could also be affected, the researchers said.

The number of prescriptions for PPIs such as lansoprazole and omeprazole – sold over the counter as Zanprol – has doubled in recent years to more than eight million a year, costing the NHS around £400 million a year. The exact number of patients on the drugs is not known because some buy them over the counter (OTC) at high street chemists.

PPIs work by blocking the action of cells called proton pumps, which produce stomach acid. Although very effective, they should only be used for a maximum of two months and preferably for between two and four weeks.

But many patients quickly find they cannot live without them and ask for repeat prescriptions from their GP or buy them at the chemist. Previous studies identified a potential link between the drugs and heart problems, although scientists conceded there was no obvious explanation for the connection.

Now experts at the Methodist Hospital Research Institute in Houston, Texas, believe they have uncovered the reason why.

After studying samples of human heart tissue, as well as carrying out experiments on mice, they found that PPIs triggered an increase in a chemical called asymmetric dimethylarginine, or ADMA, produced as the body’s cells make proteins.

It can hinder blood flow by blocking the release of nitric oxide, a gas which helps arteries to stay flexible and healthy. The latest findings, published in the journal Circulation, show PPI medicines increase ADMA levels by about 25 per cent and reduce the ability of blood vessel walls to relax by more than 30 per cent.

In a report on their findings, the researchers said that several studies have raised concern that the use of PPIs in patients with acute coronary syndrome (heart disease) may increase their risk of major adverse events.

Dr John Cooke, who heads the research group, says that whilst a plausible biological explanation has now been found to explain this, also added that the ‘surprising effect still needs further investigation’.

Standard